Boehringer Ingelheim and MD Anderson Expand their Collaboration to Accelerate Targeted Therapies for Lung Cancer
Shots:
- Boehringer Ingelheim and MD Anderson expand their 2019 joint VRDC to explore new molecules from Boehringer Ingelheim’s KRAS and TRAILR2 portfolios for lung cancer- particularly NSCLC
- The joint research will continue for 5 additional years. The extended collaboration follows successful preclinical studies in GI cancers via joint VRDC
- The expanded agreement allows the partners to expand their lung cancer indication programs targeting KRAS and TRAILR2- including Boehringer Ingelheim’s BI 1701963- BI 1823911- BI 3011441- along with bi-specific TRAILR2 agonist
Ref: Business Wire | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com